International Journal of Brain Sciences Review Article
Hypertension as a risk factor for brain stroke: From Endothelial Dysfunction to Neuronal Injury
This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.
Abstract
Hypertension is a major modifiable vascular risk factor for cerebral stroke and is strongly linked to progressive injury of the cerebral circulation. Although stroke is conventionally divided into ischemic and hemorrhagic forms, the vascular abnormalities produced by chronic hypertension can contribute to vulnerability to both. Persistent elevation of blood pressure imposes mechanical and biochemical stress on the vascular wall, promoting arterial remodeling, endothelial dysfunction, oxidative stress, impaired nitric oxide signaling, inflammation, and disruption of cerebral autoregulation. At the level of the neurovascular unit, these changes affect endothelial cells, vascular smooth muscle cells, pericytes, astrocytes, microglia, and their communication with neurons. Loss of endothelial barrier integrity can increase blood-brain barrier permeability, while impaired neurovascular coupling can reduce the ability of cerebral vessels to match local blood flow to neuronal metabolic demand. These abnormalities may promote chronic hypoperfusion, cerebral small-vessel disease, white-matter injury, microbleeds, and increased susceptibility to acute ischemic or hemorrhagic events. Following ischemic injury, a pre-existing hypertensive vascular environment may further amplify oxidative stress, inflammatory signaling, excitotoxicity, mitochondrial dysfunction, blood-brain barrier disruption, and neuronal death. This review integrates evidence describing the progression from chronic hypertension to cerebrovascular dysfunction and summarizes the interconnected mechanisms linking vascular injury with neuronal damage. Understanding these mechanisms provides a framework for identifying vascular and neurovascular processes that may be relevant to prevention of hypertension-associated cerebral injury.Keywords
References (1)
- Feigin VL, Brainin M, Norrving B, Martins S, Sacco RL, Hacke W, Fisher M, Pandian J, Lindsay P. World Stroke Organization (WSO): global stroke fact sheet 2022. International journal of stroke. 2022 Jan;17(1):18-29. 2. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. Neurology. 2021 Oct;20(10):795. 3. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016 Aug 9;134(6):441-50. 4. O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, Rao-Melacini P, Zhang X, Pais P, Agapay S, Lopez-Jaramillo P. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. The lancet. 2016 Aug 20;388(10046):761-75. 5. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality. The Lancet. 2003 Apr 19;361(9366):1391-2. 6. Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, Gregg EW, Bennett JE, Solomon B, Singleton RK, Sophiea MK. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. The lancet. 2021 Sep 11;398(10304):957-80. 7. Boehme AK, Esenwa C, Elkind MS. Stroke risk factors, genetics, and prevention. Circulation research. 2017 Feb 3;120(3):472-95. 8. Kannel WB, Wolf PA, Verter J, McNamara PM. Epidemiologic assessment of the role of blood pressure in stroke: the Framingham study. Jama. 1996 Oct 16;276(15):1269-78. 9. Arima H, Tzourio C, Anderson C, Woodward M, Bousser MG, MacMahon S, Neal B, Chalmers J. Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke. 2010 Feb 1;41(2):394-6. 10. Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive role of the nighttime blood pressure. Hypertension. 2011 Jan;57(1):3-10. 11. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, Murata M, Kuroda T, Schwartz JE, Shimada K. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003 Mar 18;107(10):1401-6. 12. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. The Lancet. 2010 Mar 13;375(9718):895-905. 13. Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. New England journal of medicine. 1998 Jun 4;338(23):1650-6. 14. Iadecola C, Yaffe K, Biller J, Bratzke LC, Faraci FM, Gorelick PB, Gulati M, Kamel H, Knopman DS, Launer LJ, Saczynski JS. Impact of hypertension on cognitive function: a scientific statement from the American Heart Association. Hypertension. 2016 Dec;68(6):e67-94. 15. Garovic VD, White WM, Vaughan L, Saiki M, Parashuram S, Garcia-Valencia O, Weissgerber TL, Milic N, Weaver A, Mielke MM. Incidence and long-term outcomes of hypertensive disorders of pregnancy. Journal of the American College of Cardiology. 2020 May 12;75(18):2323-34. 16. Strandgaard S, Olesen J, Skinhøj E, Lassen NA. Autoregulation of brain circulation in severe arterial hypertension. British medical journal. 1973 Mar 3;1(5852):507. 17. Paulson OB, Strandgaard S, Edvinsson L. Cerebral autoregulation. Cerebrovascular and brain metabolism reviews. 1990;2(2):161-92. 18. Jorgensen LG, Schroeder TV. Defective cerebrovascular autoregulation after carotid endarterectomy. European journal of vascular surgery. 1993 Jul 1;7(4):370-9. 19. Touyz RM, Alves-Lopes R, Rios FJ, Camargo LL, Anagnostopoulou A, Arner A, Montezano AC. Vascular smooth muscle contraction in hypertension. Cardiovascular research. 2018 Mar 15;114(4):529-39. 20. Panza JA, Quyyumi AA, Brush Jr JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. New England Journal of Medicine. 1990 Jul 5;323(1):22-7. 21. Förstermann U, Xia N, Li H. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circulation research. 2017 Feb 17;120(4):713-35. 22. Li H, Förstermann U. Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease. Current opinion in pharmacology. 2013 Apr 1;13(2):161-7. 23. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. nature. 1988 Mar 31;332(6163):411-5. 24. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation. 2005 Jan 25;111(3):363-8. 25. Matsuzawa Y, Kwon TG, Lennon RJ, Lerman LO, Lerman A. Prognostic value of flow‐mediated vasodilation in brachial artery and fingertip artery for cardiovascular events: a systematic review and meta‐analysis. Journal of the American Heart Association. 2015 Nov 13;4(11):e002270. 26. Griendling KK, Sorescu D, Ushio-Fukai M. NAD (P) H oxidase: role in cardiovascular biology and disease. Circulation research. 2000 Mar 17;86(5):494-501. 27. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nature reviews Drug discovery. 2011 Jun;10(6):453-71. 28. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II- mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. The Journal of clinical investigation. 1996 Apr 15;97(8):1916-23. 29. Dikalov SI, Ungvari Z. Role of mitochondrial oxidative stress in hypertension. American Journal of Physiology- Heart and Circulatory Physiology. 2013 Nov 15;305(10):H1417-27. 30. Loboda A, Damulewicz M, Pyza E, Jozkowicz A, Dulak J. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism. Cellular and molecular life sciences. 2016 Sep;73(17):3221-47. 31. Cifuentes-Pagano E, Meijles DN, Pagano PJ. The quest for selective nox inhibitors and therapeutics: challenges, triumphs and pitfalls. Antioxidants & redox signaling. 2014 Jun;20(17):2741-54. 32. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension. 2001 Sep 1;38(3):581-7. 33. Schiffrin EL. Vascular remodeling in hypertension: mechanisms and treatment. Hypertension. 2012 Feb;59(2):367-74. 34. Loirand G, Pacaud P. The role of Rho protein signaling in hypertension. Nature Reviews Cardiology. 2010 Nov;7(11):637-47. 35. Vlachopoulos MC, Aznaouridis MK, Stefanadis MC. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. Journal of the American college of cardiology. 2010 Mar 30;55(13):1318-27. 36. Sprint Mind Investigators for the SPRINT Research Group, Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, Cheung AK, Cleveland ML, Coker LH, Crowe MG, Cushman WC. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. Jama. 2019 Feb 12;321(6):553-61. 37. Bader M, Ganten D. Update on tissue renin–angiotensin systems. Journal of Molecular Medicine. 2008 Jun;86(6):615-21. 38. Widdop RE, Vinh A, Henrion D, Jones ES. VASCULAR ANGIOTENSIN AT 2 RECEPTORS IN HYPERTENSION AND AGEING. Clinical & Experimental Pharmacology & Physiology. 2008 Apr 1;35(4):386. 39. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circulation research. 2005 Apr 1;96(6):643-50. 40. Santos RA, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, Campagnole-Santos MJ. The ACE2/angiotensin-(1–7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1–7). Physiological reviews. 2017 Dec 20. 41. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nature medicine. 2011 Jul;17(7):796-808. 42. Bader ER, Pana TA, Barlas RS, Metcalf AK, Potter JF, Myint PK. Elevated inflammatory biomarkers and poor outcomes in intracerebral hemorrhage. Journal of Neurology. 2022 Dec;269(12):6330-41. 43. Yang F, Wang Z, Wei X, Han H, Meng X, Zhang Y, Shi W, Li F, Xin T, Pang Q, Yi F. NLRP3 deficiency ameliorates neurovascular damage in experimental ischemic stroke. Journal of Cerebral Blood Flow & Metabolism. 2014 Apr;34(4):660-7. 44. McMaster WG, Kirabo A, Madhur MS, Harrison DG. Inflammation, immunity, and hypertensive end-organ damage. Circulation research. 2015 Mar 13;116(6):1022-33. 45. Anrather J, Iadecola C. Inflammation and stroke: an overview. Neurotherapeutics. 2016 Oct 1;13(4):661-70. 46. Yang GY, Betz AL. Reperfusion-induced injury to the blood-brain barrier after middle cerebral artery occlusion in rats. Stroke. 1994 Aug;25(8):1658-64. 47. Rosenberg GA, Yang Y. Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurgical focus. 2007 May 1;22(5):1-9. 48. Knowland D, Arac A, Sekiguchi KJ, Hsu M, Lutz SE, Perrino J, Steinberg GK, Barres BA, Nimmerjahn A, Agalliu D. Stepwise recruitment of transcellular and paracellular pathways underlies blood-brain barrier breakdown in stroke. Neuron. 2014 May 7;82(3):603-17 49. Wardlaw JM. Blood-brain barrier and cerebral small vessel disease. Journal of the neurological sciences. 2010 Dec 15;299(1-2):66-71.. 50. Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Japanese circulation journal. 1963 Mar 20;27(3):282-93. 51. Fisher CM. Lacunar strokes and infarcts: a review. Neurology. 1982 Aug;32(8):871-6. 52. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nature medicine. 2011 Nov;17(11):1410-22. 53. Marquardt L, Geraghty OC, Mehta Z, Rothwell PM. Low risk of ipsilateral stroke in patients with asymptomatic carotid stenosis on best medical treatment: a prospective, population-based study. Stroke. 2010 Jan 1;41(1):e11-7. 54. Charcot JM. Nouvelles recherches sur la pathogenie de l'hemorrhagie cerebrale. Arch Physio (Pris). 1868;1:110- 27. 55. Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. The Lancet. 2009 May 9;373(9675):1632-44. 56. Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, Lindley R, Robinson T, Lavados P, Neal B, Hata J. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. New England Journal of Medicine. 2013 Jun 20;368(25):2355-65. 57. Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, Moy CS, Silbergleit R, Steiner T, Suarez JI, Toyoda K. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. Journal of Neurosurgical Anesthesiology. 2017;29(2):176-7. 58. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J, AtheroGene Investigators. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation. 2001 Sep 18;104(12):1336-42. 59. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. The Lancet Neurology. 2019 Jul 1;18(7):684-96. 60. Debette S, Schilling S, Duperron MG, Larsson SC, Markus HS. Clinical significance of magnetic resonance imaging markers of vascular brain injury: a systematic review and meta-analysis. JAMA neurology. 2019 Jan;76(1):81-94. 61. Bormes G, Robbin V, Chikowore T, Zhang Y, Choudhury A, Hazelhurst S, Hanchard NA, Adebamowo SN, Adeyemo AA, Tayo B. Pathway-specific polygenic risk scores for blood pressure traits in a West African cohort. Frontiers in Cardiovascular Medicine. 2026 Mar 13;13:1707809. 62. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet. 2016 Mar 5;387(10022):957-67. 63. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. New England Journal of Medicine. 2015 Nov 26;373(22):2103-16. 64. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. The Lancet. 2005 Sep 10;366(9489):895-906. 65. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet. 2002 Mar 23;359(9311):995-1003. 66. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019 Dec;50(12):e344- 418. 67. Hemphill III JC, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, Fung GL, Goldstein JN, Macdonald RL, Mitchell PH, Scott PA. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015 Jul;46(7):2032-60. 68. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJ. Antiinflammatory therapy with canakinumab for atherosclerotic disease. New England journal of medicine. 2017 Sep 21;377(12):1119-31. 69. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C. Efficacy and safety of low-dose colchicine after myocardial infarction. New England journal of medicine. 2019 Dec 26;381(26):2497-505. 70. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New england journal of medicine. 2015 Nov 26;373(22):2117-28. 71. Bagheri M, Agrawal V, Annis J, Shi M, Ferguson JF, Freiberg MS, Mosley JD, Brittain EL. Genetics of pulmonary pressure and right ventricle stress identify diabetes as a causal risk factor. Journal of the American Heart Association. 2023 Aug 1;12(15):e029190. 72. Tang WW, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease. Circulation research. 2017 Mar 31;120(7):1183-96. 73. Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, Foster D, Huang SA, Rhyee S, Sweetser MT, Bakris GL. Zilebesiran, an RNA interference therapeutic agent for hypertension. New England Journal of Medicine. 2023 Jul 20;389(3):228-38. 74. Santisteban MM, Iadecola C, Carnevale D. Hypertension, neurovascular dysfunction, and cognitive impairment. Hypertension. 2023 Jan;80(1):22-34..